ALSO NOTED: Promacta gets priority review; GTx drug hits endpoint; Alexza touts IIa data; and much more...

> Glaxo's Promacta, a bleeding disorder drug, will be given a priority review by the FDA. Release

> GTx announced that an 80 mg dose of toremifene citrate experienced reduced rates of hot flashes in prostate cancer patients on ADT therapy, hitting a secondary endpoint in a late-stage trial. Report

> Alexza Pharmaceuticals announced that its Phase IIa trial for its migraine drug AZ-104 hits its primary endpoint of two-hour pain relief after two doses compared to placebo. Report

> Denmark's Neurosearch reported positive data for its obesity drug. "Neurosearch considers the TIPO-2 results highly supportive for the continued development of Tesofensine both in terms of superior efficacy and safety." Release

> Valeant Pharmaceuticals has sold its Asian operations to Invida Pharmaceutical for $37.8 million. Release

> AEterna Zentaris and Paladin Labs have inked a sales deal on all rights related to miltefosine for Cdn$9.125 million in cash. Release

> A hedge fund has cut its holdings in CV Therapeutics to 2.1 percent. Report

> Put your cards on the table, ladies and gentlemen. A U.K. minister is calling on drug companies to hand over all their data on antidepressants to the National Institute for Health and Clinical Excellence. Report

> Want to know what happens inside a pharma company during a recall crisis? Check out Sunday's Chicago Tribune, which details the behind-the-scenes scramble at Baxter. Report

> Celebs may help sell magazines but do they really help market drugs? In the wake of Robert Jarvik's public downfall from Pfizer's pitchman-pedestal, advertising experts are wondering. Report

And Finally... Narcoleptics experience a high rate of eating disorders, with binge eating and food craving at the top of the list. Release

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.